Cargando…
Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma
BACKGROUND: Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such approach. Here we investigated the concordance between mutations found in the pri...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321709/ https://www.ncbi.nlm.nih.gov/pubmed/30611220 http://dx.doi.org/10.1186/s12885-018-5195-7 |
_version_ | 1783385506672803840 |
---|---|
author | Choi, Man Hung Mejlænder-Andersen, Eline Manueldas, Sophia El Jellas, Khadija Steine, Solrun J. Tjensvoll, Kjersti Sætran, Hege Aase Knappskog, Stian Hoem, Dag Nordgård, Oddmund Hovland, Randi Molven, Anders |
author_facet | Choi, Man Hung Mejlænder-Andersen, Eline Manueldas, Sophia El Jellas, Khadija Steine, Solrun J. Tjensvoll, Kjersti Sætran, Hege Aase Knappskog, Stian Hoem, Dag Nordgård, Oddmund Hovland, Randi Molven, Anders |
author_sort | Choi, Man Hung |
collection | PubMed |
description | BACKGROUND: Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such approach. Here we investigated the concordance between mutations found in the primary tumor and pancreatic juice from the same patient. METHODS: Amplicon-based targeted deep sequencing was performed on samples from 21 patients with pancreatic ductal adenocarcinoma (PDAC) who had undergone Whipple’s operation. Mutation profiles were determined in formalin-fixed sections of the primary tumor and in pancreatic juice sampled from the main pancreatic duct during surgery. RESULTS: Using a cut-off of 3% for variant allele frequency, KRAS mutations were detected in 20/21 primary tumors (95%) and in 15/21 (71%) juice samples. When also considering low-frequency variants, KRAS mutations were found in 20/21 juice samples. Most juice samples exhibited multiple KRAS variants not seen in the primary tumor, and only in 11 cases (52%) did the most abundant variant of the juice correspond to the KRAS mutation detected in the tumor. TP53 mutations were found in 16 tumors (76%) and six juice samples (29%). Among the positive juice samples, only one exhibited more than a single TP53 mutation. Detection of both KRAS and TP53 mutations was fully concordant in the primary tumor and juice sample in 7/21 cases (33%). CONCLUSIONS: Pancreatic juice from PDAC patients is rich in KRAS mutations often not seen in the primary tumor and possibly reflecting precancerous lesions in other regions of the pancreas. The inclusion of TP53 mutation detection and additional markers must therefore be considered for fully exploiting the clinical potential of pancreatic juice samples in early cancer detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-5195-7) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6321709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63217092019-01-09 Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma Choi, Man Hung Mejlænder-Andersen, Eline Manueldas, Sophia El Jellas, Khadija Steine, Solrun J. Tjensvoll, Kjersti Sætran, Hege Aase Knappskog, Stian Hoem, Dag Nordgård, Oddmund Hovland, Randi Molven, Anders BMC Cancer Research Article BACKGROUND: Reliable methods are needed to identify patients with early-stage cancer or high-grade precancerous lesions in the pancreas. Analysis of pancreatic juice to detect somatic mutations could represent one such approach. Here we investigated the concordance between mutations found in the primary tumor and pancreatic juice from the same patient. METHODS: Amplicon-based targeted deep sequencing was performed on samples from 21 patients with pancreatic ductal adenocarcinoma (PDAC) who had undergone Whipple’s operation. Mutation profiles were determined in formalin-fixed sections of the primary tumor and in pancreatic juice sampled from the main pancreatic duct during surgery. RESULTS: Using a cut-off of 3% for variant allele frequency, KRAS mutations were detected in 20/21 primary tumors (95%) and in 15/21 (71%) juice samples. When also considering low-frequency variants, KRAS mutations were found in 20/21 juice samples. Most juice samples exhibited multiple KRAS variants not seen in the primary tumor, and only in 11 cases (52%) did the most abundant variant of the juice correspond to the KRAS mutation detected in the tumor. TP53 mutations were found in 16 tumors (76%) and six juice samples (29%). Among the positive juice samples, only one exhibited more than a single TP53 mutation. Detection of both KRAS and TP53 mutations was fully concordant in the primary tumor and juice sample in 7/21 cases (33%). CONCLUSIONS: Pancreatic juice from PDAC patients is rich in KRAS mutations often not seen in the primary tumor and possibly reflecting precancerous lesions in other regions of the pancreas. The inclusion of TP53 mutation detection and additional markers must therefore be considered for fully exploiting the clinical potential of pancreatic juice samples in early cancer detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-5195-7) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-05 /pmc/articles/PMC6321709/ /pubmed/30611220 http://dx.doi.org/10.1186/s12885-018-5195-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Choi, Man Hung Mejlænder-Andersen, Eline Manueldas, Sophia El Jellas, Khadija Steine, Solrun J. Tjensvoll, Kjersti Sætran, Hege Aase Knappskog, Stian Hoem, Dag Nordgård, Oddmund Hovland, Randi Molven, Anders Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma |
title | Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma |
title_full | Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma |
title_fullStr | Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma |
title_full_unstemmed | Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma |
title_short | Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma |
title_sort | mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321709/ https://www.ncbi.nlm.nih.gov/pubmed/30611220 http://dx.doi.org/10.1186/s12885-018-5195-7 |
work_keys_str_mv | AT choimanhung mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT mejlænderanderseneline mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT manueldassophia mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT eljellaskhadija mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT steinesolrunj mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT tjensvollkjersti mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT sætranhegeaase mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT knappskogstian mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT hoemdag mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT nordgardoddmund mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT hovlandrandi mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma AT molvenanders mutationanalysisbydeepsequencingofpancreaticjuicefrompatientswithpancreaticductaladenocarcinoma |